{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:18:04Z","timestamp":1788477484314,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772183"],"award-info":[{"award-number":["81772183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31600132"],"award-info":[{"award-number":["31600132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People\u2019s Republic of China","doi-asserted-by":"crossref","award":["2018ZX10731101-003-004"],"award-info":[{"award-number":["2018ZX10731101-003-004"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"crossref","award":["20180101127JC"],"award-info":[{"award-number":["20180101127JC"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00280-018-3582-z","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T11:50:48Z","timestamp":1523965848000},"page":"1083-1093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification"],"prefix":"10.1007","volume":"81","author":[{"given":"Bo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyou","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam Kumari","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4456-840X","authenticated-orcid":false,"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"3582_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134","journal-title":"N Engl J Med"},{"key":"3582_CR2","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312\u20133318","journal-title":"J Clin Oncol"},{"key":"3582_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722\u2013731","journal-title":"N Engl J Med"},{"key":"3582_CR4","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584\u20133590","journal-title":"J Clin Oncol"},{"key":"3582_CR5","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","volume":"27","author":"BI Rini","year":"2009","unstructured":"Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462\u20134468","journal-title":"J Clin Oncol"},{"key":"3582_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer cell 5:417\u2013421","journal-title":"Cancer cell"},{"key":"3582_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev.pharmtox.051208.165340","volume":"49","author":"AL Schwartz","year":"2009","unstructured":"Schwartz AL, Ciechanover A (2009) Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 49:73\u201396","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3582_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrc1881","volume":"6","author":"KI Nakayama","year":"2006","unstructured":"Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6:369\u2013381","journal-title":"Nat Rev Cancer"},{"key":"3582_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrm1547","volume":"6","author":"MD Petroski","year":"2005","unstructured":"Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6:9\u201320","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3582_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/416703a","volume":"416","author":"N Zheng","year":"2002","unstructured":"Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, Conaway RC, Conaway JW, Harper JW, Pavletich NP (2002) Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416:703\u2013709","journal-title":"Nature"},{"key":"3582_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/cdd.2012.113","volume":"20","author":"D Yang","year":"2013","unstructured":"Yang D, Li L, Liu H, Wu L, Luo Z, Li H, Zheng S, Gao H, Chu Y, Sun Y, Liu J, Jia L (2013) Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells. Cell Death Differ 20:235\u2013247","journal-title":"Cell Death Differ"},{"key":"3582_CR12","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1074\/jbc.M110.188425","volume":"286","author":"L Jia","year":"2011","unstructured":"Jia L, Bickel JS, Wu J, Morgan MA, Li H, Yang J, Yu X, Chan RC, Sun Y (2011) RBX1 (RING box protein 1) E3 ubiquitin ligase is required for genomic integrity by modulating DNA replication licensing proteins. J Biol Chem 286:3379\u20133386","journal-title":"J Biol Chem"},{"key":"3582_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccr.2011.01.002","volume":"19","author":"IR Watson","year":"2011","unstructured":"Watson IR, Irwin MS, Ohh M (2011) NEDD8 pathways in cancer. Sine Quibus Non Cancer cell 19:168\u2013176","journal-title":"Sine Quibus Non Cancer cell"},{"key":"3582_CR14","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","volume":"116","author":"MA Milhollen","year":"2010","unstructured":"Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy TA, Yu J, Zhang J, Bolen JB, Smith PG (2010) MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 116:1515\u20131523","journal-title":"Blood"},{"key":"3582_CR15","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-12-3212","volume":"19","author":"ST Nawrocki","year":"2013","unstructured":"Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A, Carew JS (2013) Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res 19:3577\u20133590","journal-title":"Clin Cancer Res"},{"key":"3582_CR16","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1038\/ncomms4733","volume":"5","author":"P Xie","year":"2014","unstructured":"Xie P, Zhang M, He S, Lu K, Chen Y, Xing G, Lu Y, Liu P, Li Y, Wang S, Chai N, Wu J, Deng H, Wang HR, Cao Y, Zhao F (2014) Cui Y3, Wang J3, He F3, Zhang L8. The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis. Nat Commun 5:3733","journal-title":"Nat Commun"},{"key":"3582_CR17","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1089\/ars.2013.5795","volume":"21","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Morgan MA, Sun Y (2014) Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. Antioxid Redox Signal 21:2383\u20132400","journal-title":"Antioxid Redox Signal"},{"key":"3582_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10637-016-0348-5","volume":"34","author":"S Bhatia","year":"2016","unstructured":"Bhatia S, Pavlick AC, Boasberg P, Thompson JA, Mulligan G, Pickard MD, Faessel H, Dezube BJ, Hamid O (2016) A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924\/MLN4924) in patients with metastatic melanoma. Invest New Drugs 34:439\u2013449","journal-title":"Invest New Drugs"},{"key":"3582_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","volume":"22","author":"JJ Shah","year":"2016","unstructured":"Shah JJ, Jakubowiak AJ, O\u2019Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S (2016) Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma. Clin Cancer Res 22:34\u201343","journal-title":"Clin Cancer Res"},{"key":"3582_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1078-0432.CCR-15-1338","volume":"22","author":"J Sarantopoulos","year":"2016","unstructured":"Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD (2016) Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924\/MLN4924) in patients with advanced solid tumors. Clin Cancer Res 22:847\u2013857","journal-title":"Clin Cancer Res"},{"key":"3582_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.13323","volume":"169","author":"RT Swords","year":"2015","unstructured":"Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, Hua Z, Blakemore SJ, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC (2015) Pevonedistat (MLN4924), a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol 169:534\u2013543","journal-title":"Br J Haematol"},{"key":"3582_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.chom.2016.09.013","volume":"20","author":"W Wei","year":"2016","unstructured":"Wei W, Guo H, Chang J, Yu Y, Liu G, Zhang N, Willard SH, Zheng S, Yu XF (2016) ICAM-5\/telencephalin is a functional entry receptor for enterovirus D68. Cell Host Microbe 20:631\u2013641","journal-title":"Cell Host Microbe"},{"key":"3582_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrurol.2010.46","volume":"7","author":"WH Chow","year":"2010","unstructured":"Chow WH, Dong LM, Devesa SSD (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7:245\u2013257","journal-title":"Nat Rev Urol"},{"key":"3582_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Statistics (2017) CA Cancer J Clin 2017 67:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"3582_CR25","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1101\/gr.131110.111","volume":"22","author":"WM Linehan","year":"2012","unstructured":"Linehan WM (2012) Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res 22:2089\u20132100","journal-title":"Genome Res"},{"key":"3582_CR26","doi-asserted-by":"publisher","first-page":"e2859","DOI":"10.1038\/cddis.2017.252","volume":"8","author":"Z Chen","year":"2017","unstructured":"Chen Z, Zhang J, Zhang Z, Feng Z, Wei J, Lu J, Fang Y, Liang Y, Cen J, Pan Y, Huang Y, Zhou F, Chen W, Luo J (2017) The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2. Cell Death Dis 8:e2859","journal-title":"Cell Death Dis"},{"key":"3582_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J (2016) Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539:112\u2013117","journal-title":"Nature"},{"key":"3582_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research N","year":"2013","unstructured":"Cancer Genome Atlas Research N (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43\u201349","journal-title":"Nature"},{"key":"3582_CR29","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, Langston SP (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458:732\u2013736","journal-title":"Nature"},{"key":"3582_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1158\/0008-5472.CAN-12-1729","volume":"73","author":"JL Blank","year":"2013","unstructured":"Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, Lightcap ES (2013) Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res 73:225\u2013234","journal-title":"Cancer Res"},{"key":"3582_CR31","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1158\/0008-5472.CAN-10-2122","volume":"71","author":"MA Milhollen","year":"2011","unstructured":"Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B (2011) Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 71:3042\u20133051","journal-title":"Cancer Res"},{"key":"3582_CR32","doi-asserted-by":"publisher","first-page":"10310","DOI":"10.1158\/0008-5472.CAN-10-2062","volume":"70","author":"JJ Lin","year":"2010","unstructured":"Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A (2010) NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 70:10310\u201310320","journal-title":"Cancer Res"},{"key":"3582_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cell.2011.09.019","volume":"147","author":"MJ Emanuele","year":"2011","unstructured":"Emanuele MJ, Elia AE, Xu Q, Thoma CR, Izhar L, Leng Y, Guo A, Chen YN, Rush J, Hsu PW, Yen HC, Elledge SJ (2011) Global identification of modular cullin-RING ligase substrates. Cell 147:459\u2013474","journal-title":"Cell"},{"key":"3582_CR34","doi-asserted-by":"publisher","first-page":"e1059","DOI":"10.1038\/cddis.2014.21","volume":"5","author":"WT Yao","year":"2014","unstructured":"Yao WT, Wu JF, Yu GY, Wang R, Wang K, Li LH, Chen P, Jiang YN, Cheng H, Lee HW, Yu J, Qi H, Yu XJ, Wang P, Chu YW, Yang M, Hua ZC, Ying HQ, Hoffman RM, Jeong LS, Jia LJ (2014) Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Cell Death Dis 5:e1059","journal-title":"Cell Death Dis"},{"key":"3582_CR35","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.molcel.2009.09.004","volume":"35","author":"Y Chen","year":"2009","unstructured":"Chen Y, Yang Z, Meng M, Zhao Y, Dong N, Yan H, Liu L, Ding M, Peng HB, Shao F (2009) Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. Mol Cell 35:841\u2013855","journal-title":"Mol Cell"},{"key":"3582_CR36","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.4161\/auto.22024","volume":"8","author":"D Yang","year":"2012","unstructured":"Yang D, Zhao Y, Liu J, Sun Y, Jia L (2012) Protective autophagy induced by RBX1\/ROC1 knockdown or CRL inactivation via modulating the DEPTOR-MTOR axis. Autophagy 8:1856\u20131858","journal-title":"Autophagy"},{"key":"3582_CR37","doi-asserted-by":"publisher","first-page":"e101844","DOI":"10.1371\/journal.pone.0101844","volume":"9","author":"S Cukras","year":"2014","unstructured":"Cukras S, Morffy N, Ohn T, Kee Y (2014) Inactivating UBE2M impacts the DNA damage response and genome integrity involving multiple cullin ligases. PLoS One 9:e101844","journal-title":"PLoS One"},{"key":"3582_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.molcel.2009.01.011","volume":"33","author":"DT Huang","year":"2009","unstructured":"Huang DT, Ayrault O, Hunt HW, Taherbhoy AM, Duda DM, Scott DC, Borg LA, Neale G, Murray PJ, Roussel MF, Schulman BA (2009) E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. Mol Cell 33:483\u2013495","journal-title":"Mol Cell"},{"key":"3582_CR39","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.4161\/cbt.21046","volume":"13","author":"KK Haagenson","year":"2012","unstructured":"Haagenson KK, Tait L, Wang J, Shekhar MP, Polin L, Chen W, Wu GS (2012) Cullin-3 protein expression levels correlate with breast cancer progression. Cancer Biol Ther 13:1042\u20131046","journal-title":"Cancer Biol Ther"},{"key":"3582_CR40","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/jcmm.12811","volume":"20","author":"MS Hung","year":"2016","unstructured":"Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Lung JH, Yang CT, Liu ST (2016) Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells. J Cell Mol Med 20:1295\u20131306","journal-title":"J Cell Mol Med"},{"key":"3582_CR41","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14:1649\u20131657","journal-title":"Clin Cancer Res"},{"key":"3582_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519\u2013527","journal-title":"Lancet"},{"key":"3582_CR43","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","volume":"17","author":"S Arastu-Kapur","year":"2011","unstructured":"Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 17:2734\u20132743","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3582-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3582-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3582-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T08:52:31Z","timestamp":1589878351000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3582-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["3582"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3582-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"7 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving animal experiments were in accordance with the ethical standards of China research committee and the protocol approved by the Ethics Committee of the First Hospital of Jilin University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}